Literature DB >> 7969070

Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.

Z Szallasi1, M F Denning, C B Smith, A A Dlugosz, S H Yuspa, G R Pettit, P M Blumberg.   

Abstract

Bryostatin 1 and phorbol-12-myristate-13-acetate (PMA) are both potent activators of protein kinase C (PKC), although in primary mouse keratinocytes bryostatin 1 does not induce differentiation and blocks PMA-induced differentiation. We report here that in primary mouse keratinocytes PMA caused translocation of PKC-epsilon to the Triton X-100-soluble fraction with an approximately 2-order of magnitude higher potency, compared with translocation of PKC-alpha and PKC-delta. The kinetics of translocation were fastest for PKC-epsilon, slower for PKC-alpha, and slowest for PKC-delta. At 5-20 min bryostatin 1 showed potency similar to that of PMA for translocating PKC-alpha, higher potency for translocating PKC-delta, and lower potency for translocating PKC-epsilon. At a later time (6 hr), bryostatin 1 was 1-2 orders magnitude more potent than PMA for causing loss of PKC-alpha, -delta, and -epsilon from the soluble fraction. Bryostatin 1 was 40-fold more potent than PMA for down-regulating PKC-alpha and showed a biphasic dose-response curve for down-regulating PKC-delta. Bryostatin 1 at 0.1-1 nM down-regulated PKC-delta to a similar extent as did PMA. Bryostatin 1 at 100 nM to 1 microM, on the other hand, failed to induce down-regulation, and these high (100 nM to 1 microM) doses of bryostatin 1 showed noncompetitive inhibition of PKC-delta down-regulation by 1 microM PMA after coapplication. This protected portion of PKC-delta retained kinase activity. The dose-response curve for bryostatin 1 protection of PKC-delta from down-regulation by PMA correlated with bryostatin 1 inhibition of the effects of PMA on cornified envelope formation (a marker of differentiation) and epidermal growth factor binding. Although PKC-epsilon was readily translocated by both PMA and bryostatin 1, the PKC-epsilon originally associated with the particulate fraction showed no down-regulation by either of these agents. We hypothesize that differential regulation of PKC isozymes by PMA and bryostatin 1 may contribute to the different patterns of biological responses that they induce.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969070

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  28 in total

1.  Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-delta.

Authors:  Yongmei Pu; Susan H Garfield; Noemi Kedei; Peter M Blumberg
Journal:  J Biol Chem       Date:  2008-11-10       Impact factor: 5.157

Review 2.  Transcription factor regulation of epidermal keratinocyte gene expression.

Authors:  R L Eckert; J F Welter
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

3.  Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.

Authors:  Thomas J Cummins; Noemi Kedei; Agnes Czikora; Nancy E Lewin; Sharon Kirk; Mark E Petersen; Kevin M McGowan; Jin-Qiu Chen; Xiaoling Luo; Randall C Johnson; Sarangan Ravichandran; Peter M Blumberg; Gary E Keck
Journal:  Chembiochem       Date:  2018-03-25       Impact factor: 3.164

4.  Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.

Authors:  N Kedei; A Telek; A M Michalowski; M B Kraft; W Li; Y B Poudel; A Rudra; M E Petersen; G E Keck; P M Blumberg
Journal:  Biochem Pharmacol       Date:  2012-11-09       Impact factor: 5.858

5.  Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism.

Authors:  François Renault-Mihara; Frédéric Beuvon; Xavier Iturrioz; Brigitte Canton; Sophie De Bouard; Nadine Léonard; Shahul Mouhamad; Ariane Sharif; Joe W Ramos; Marie-Pierre Junier; Hervé Chneiweiss
Journal:  Mol Biol Cell       Date:  2006-09-20       Impact factor: 4.138

Review 6.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

7.  Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.

Authors:  Jessica S Kelsey; Christophe Cataisson; Jinqiu Chen; Michelle A Herrmann; Mark E Petersen; David O Baumann; Kevin M McGowan; Stuart H Yuspa; Gary E Keck; Peter M Blumberg
Journal:  Mol Carcinog       Date:  2016-02-09       Impact factor: 4.784

8.  The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.

Authors:  Noemi Kedei; Andrea Telek; Alexandra Czap; Emanuel S Lubart; Gabriella Czifra; Dazhi Yang; Jinqiu Chen; Tyler Morrison; Paul K Goldsmith; Langston Lim; Poonam Mannan; Susan H Garfield; Matthew B Kraft; Wei Li; Gary E Keck; Peter M Blumberg
Journal:  Biochem Pharmacol       Date:  2011-03-30       Impact factor: 5.858

9.  Differential effects of bryostatin 1 and 12-O-tetradecanoylphorbol-13-acetate on the regulation and activation of RasGRP1 in mouse epidermal keratinocytes.

Authors:  Matthew C Tuthill; Carolyn E Oki; Patricia S Lorenzo
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

10.  Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.

Authors:  Maria J Comin; Gabriella Czifra; Noemi Kedei; Andrea Telek; Nancy E Lewin; Sofiya Kolusheva; Julia F Velasquez; Ryan Kobylarz; Raz Jelinek; Peter M Blumberg; Victor E Marquez
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.